EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
暂无分享,去创建一个
[1] H. Groen,et al. Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study , 2023, The Lancet regional health. Europe.
[2] Daniel Lam,et al. Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations , 2022, Medicinal Chemistry Research.
[3] E. Smit,et al. Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design. , 2021, Future oncology.
[4] Wen-jun Tian,et al. Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer , 2021, Current opinion in oncology.
[5] N. Pavlakis,et al. EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. , 2021, Clinical lung cancer.
[6] Mark S. Johnson,et al. Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations , 2021, Cancers.
[7] J. Neal,et al. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. , 2021, Cancer discovery.
[8] A. Cardona,et al. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. , 2020, Cancer Treatment Reviews.
[9] S. Heo,et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. , 2020, Cancer discovery.
[10] Peter T. Harrison,et al. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer , 2020, Seminars in cancer biology.
[11] S. Ou,et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. , 2020, Lung cancer.
[12] Minghui Wang,et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer , 2019, BMC Cancer.
[13] Paul H. Huang,et al. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer , 2019, Signal Transduction and Targeted Therapy.
[14] H. Ji,et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] C. Blakely,et al. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer , 2019, Current Oncology Reports.
[16] R. Rosell,et al. EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP). , 2018, Lung cancer.
[17] J. McPherson,et al. Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] Zhe-feng Liu,et al. Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients , 2018, OncoTargets and therapy.
[19] C. Langer,et al. Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. , 2018, JCO precision oncology.
[20] J. Ahn,et al. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea , 2018, Cancer research and treatment : official journal of Korean Cancer Association.
[21] Kwok-Kin Wong,et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer , 2018, Nature Medicine.
[22] R. McCormack,et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). , 2015, American journal of cancer research.
[23] Geoffrey R. Oxnard,et al. Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer , 2013, Science Translational Medicine.
[24] Suzanne E Dahlberg,et al. Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] M. Ladanyi,et al. Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas , 2012, Clinical Cancer Research.
[26] M. Meyerson,et al. Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.
[27] M. Ladanyi,et al. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.
[28] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[29] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.